Summary
Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta- thalassemia and other chronic anemias.
The global Deferasirox market is expected to reach xxx Million USD by 2025, with a CAGR of xx% from 2020 to 2025.
Further key aspects of the report indicate that:
Chapter 1: Market Definition and Segment by Type, End-Use & Major Regions Market Size
Chapter 2: Global Production & Consumption Market by Type and End-Use
Chapter 3: Europe Production & Consumption Market by Type and End-Use
Chapter 4: America Production & Consumption Market by Type and End-Use
Chapter 5: Asia Production & Consumption Market by Type and End-Use
Chapter 6: Oceania Production & Consumption Market by Type and End-Use
Chapter 7: Africa Production & Consumption Market by Type and End-Use
Chapter 8: Global Market Forecast by Type, End-Use and Region
Chapter 9: Company information, Sales, Cost, Margin, news etc.
Chapter 10: Market Competition by Companies and Market Concentration Ratio
Chapter 11: Market Impact by Coronavirus.
Chapter 12: Industry Summary
.
Market Segment as follows:
Key Companies:
Novartis
Cipla
Sun Pharma
Natco Pharma
Key Types
500 mg/Tablet
250 mg/Tablet
125 mg/Tablet
Others
Key End-Use
Transfusional Iron Overload
NTDT Caused Iron Overload
This report can be dispatched within 24-48 Hours.